Benign prostatic hyperplasia (BPH) is an agerelated disorder, found in a majority of men by the time the seventies are reached. Only a proportion of these will undergo surgical intervention, however; in the USA it has been estimated that the probability ofa 40 year old man undergoing a prostatectomy during is lifetime is 29%.' This suggests that there are large numbers of men with enlarged prostates and symptoms of bladder outflow obstruction who for one reason or another are at present untreated, and this is confirmed by population surveys.24 What do we know about the natural history of BPH and what ifanything can be done to favourably modify it? What are the results of surgical treatment and what alternatives to surgery are available in the management of BPH? How can we identify and optimize the management of BPH in patients with different stages of the disease? These questions will be addressed in this article and future approaches to the management of BPH identified.
Introduction
Benign prostatic hyperplasia (BPH) is an agerelated disorder, found in a majority of men by the time the seventies are reached. Only a proportion of these will undergo surgical intervention, however; in the USA it has been estimated that the probability ofa 40 year old man undergoing a prostatectomy during is lifetime is 29%.' This suggests that there are large numbers of men with enlarged prostates and symptoms of bladder outflow obstruction who for one reason or another are at present untreated, and this is confirmed by population surveys. 24 What do we know about the natural history of BPH and what ifanything can be done to favourably modify it? What are the results of surgical treatment and what alternatives to surgery are available in the management of BPH? How can we identify and optimize the management of BPH in patients with different stages of the disease? These questions will be addressed in this article and future approaches to the management of BPH identified.
Aetiology of BPH
Prostatic hyperplasia is essentially a nodular condition arising in the periurethral glandular tissue. The process originates in the mid-prostatic urethra in the region of the entry of the ejaculatory ducts.5 Nodules enlarge and coalesce, causing inward compression of the prostatic urethra and outward displacement of the true prostatic tissue. The latter therefore becomes compressed as a narrow layer surrounding the enlarging hyperplastic tissue, separated from it by a mass of smooth muscle fibres.
Several cell types are concerned in the development of benign prostatic hyperplasia, including smooth muscle fibres, myoepithelial cells, fibroblasts and glandular epithelial cells. Within enlarging nodules the usual intercellular relationships are altered due to the varying rates of growth of the different cell types.6 Stereological studies have indicated that the increase in the volume of the stromal (smooth muscle and collagen) element is twice that of the glandular element. 7 The aetiology of BPH is uncertain, but the prostate will develop, maintain normal size and function, and become hyperplastic only in men with normal androgen production. The principal prostatic androgen is dihydrotestosterone (DHT), an alpha-reduced metabolite of testosterone.
After the work of Siiteri and Wilson,8 it was thought for years that the prostates of men with BPH contained 3-4-fold higher tissue concentrations of DHT than normal glands, and this was considered fundamental to the pathogenic process. However this was later disputed by Walsh et al.,9 and in fact BPH probably occurs in glands with normal levels of DHT or at least less elevated than previously thought. Recent research has focused on the possibilities of increased densities of androgen receptor populations and enhanced expressions of growth factors as pathogenic factors, with DHT playing essentially a permissive role.
Oestrogens are also thought possibly to have a role. Serum levels of 17-oestradiol increase with age, and the net effect is to increase the oestradiol/ testosterone ratio. This may be relevant to the development of BPH as prostate stroma contains high levels of oestrogen receptors, and BPH is primarily a stromal disease. Further, 1 7-oestradiol has been shown to enhance the androgen receptor content of the prostate.'0
In conclusion, we can say that BPH is a nodular condition affecting both stromal and glandular elements of the periurethral part of the prostate gland in the ageing male. Evidence strongly supports a key role for androgen-mediated factors in the pathogenesis of BPH, with a possible supporting role for oestrogens. obstruction arises when the enlarging lobes of the prostate compress the urethra and impair bladder emptying. The response of the detrusor muscle to the obstruction varies and has a bearing on the urinary symptom complex as well as the pathological sequelae. The common symptoms attributed to bladder outflow obstruction due to BPH are hesitancy, a poor stream and terminal dribbling. The symptoms due to the response ofthe bladder to the outlet obstruction include frequency, urgency, nocturia and sometimes urge incontinence. Any or all of these symptoms may be present to a varying degree and of themselves are an unreliable index of the degree of obstruction or of prognosis in an individual case. Some of these symptoms, particularly frequency, urgency and nocturia, may occur in patients who do not have outflow obstruction and hence objective evidence must be obtained to make this diagnosis.
Investigations
Patients presenting with symptoms suggestive of bladder outflow obstruction should complete a frequency/volume chart over the course of a week.
An estimate of the daily fluid intake is also useful information and may draw the patients' attention to a correctable cause of urinary frequency. A flow study is a necessary prerequisite to the diagnosis of outflow obstruction. This is undertaken by getting the patient to void into a flow meter which measures the volume of urine passed per unit time. Most flow meters give a graphic report and record of the flow pattern, indicating the degree of hesi- 2.5%, attributed mainly to a lower incidence of pulmonary embolus and myocardial infarction. It is known that the longer the resection time the greater the incidence of perioperative and postoperative complications.'2"3 This means that the larger the prostate or the less experienced the operator then the more complications are likely to be encountered. Mortality is known to be higher in non-specialist centres'4" 5 and approaching 20% of TURs will need reoperation after a 10 year followup period.'6 A retrospective review from three different countries'7 has confirmed the increased reoperation rate after TUR, but also surprisingly that there was a small but significantly increased risk of death, mainly from cardiovascular causes, when compared with the open operation, contradicting earlier data. The possible reasons for this remain obscure and are well reviewed in a leading article'8 that pleads the case that there is 'no room for complacency' by urologists.
Non-surgical treatment of BPH There are two components contributing to bladder outflow obstruction by BPH: 'dynamic' and 'static'. The dynamic component is due to the smooth muscle component of BPH, its capsule and the bladder neck. The muscle cells are rich in alpha-receptors and respond to adrenergic stimulation by contraction and hence an increase in pressure within the prostatic urethra. Alphablockade therefore, by reducing muscular tone, should be beneficial in treating bladder outflow obstruction due to BPH. The static component of outflow obstruction due to BPH is due to the physical size of the fibroadenomatous enlargement of the prostate obstructing, distorting and compressing the urethra. As BPH is thought to be due to an alteration in the androgen/oestrogen ratio favouring oestrogen with advancing age, several therapeutic options become apparent to alter this state of affairs favourably.
Treatment ofthe dynamic component: alpha adrenergic blockade
Caine & Perlberg'9 first described alpha-blockade in the management of bladder outflow obstruction due to BPH. Phenoxybenzamine, however, blocked both al and a2 receptors and the incidence of side effects, mainly headaches, dizziness and postural hypotension, occurred in 30% of patients requiring cessation of treatment in 10%. The presence of cerebrovascular disease or recent myocardial infarction were contraindications to treatment. Since that time more selective l1 blockers have been studied which exhibit fewer side effects.
Prazosin,20 terazosin,2' and indoramin22 have been shown to be beneficial in terms of improving the urinary flow rate and reducing urinary frequency. There are no long-term treatment results reported and the role of this group of drugs is at present to alleviate the symptoms ofthose patients waiting for surgery who do not experience side effects of the medication. Although dilatation of the bladder neck and prostate is an old concept,2425 the recent interest in transurethral balloon dilatation of the prostate has developed from the success of transluminal angioplasty.26'27 The specially designed balloon is accurately inserted into the prostatic urethra either under direct vision or ultrasound control. Local urethral anaesthesia can be utilized in the unfit patient. The balloon is distended until rupture of the anterior commissure or prostate capsule occurs although this is not essential to achieve success in terms of an improved flow rate.28 No long-term results are available.
Intra-prostatic stents
An increasing range of stents for insertion into the prostatic urethra under local anaesthesia are now undergoing evaluation. These stents may be plastic coils for temporary use in the very poor risk patient or meshed metal tubes or coils for the longer term. Encrustation and displacement are not infrequent problems29 but an expanding stainless steel coil (urolumeTM) has already been shown to be of value in urethral strictures30-3 as it becomes embedded and eventually covered by the urothelium. Preliminary results of the same stent used in patients with BPH and unfit for surgery have recently been reported.33" A gold-plated spiral (ProstaKath) is under evaluation and a rigid titanium stent (developed by ASI) inserted over a balloon into the prostatic urethra which is then expanded. All of these stents hold open the prostatic urethra by separating the lateral lobes of the prostate, are easy to insert and the newer designs minimize the risk of encrustation.
Microwave
Since the first reports of local microwave heat therapy36'37 applied by special probes either per rectum or perurethrally to the prostate this treatment has received a lot of publicity in the national press. Unfortunately at present there is little in the way of objective evidence to support the claims of the manufacturers of the rival devices. The technology is being further refined and developed so that increased heat is applied to the prostate with protection by simulatenous cooling of the urethral mucosa and immediate periurethral tissue. 
